Aarti Pharma Labs
add_icon

Aarti Pharma Labs

650.85
-27.80
(-4.10%)
Market Cap
5,899.78 Cr
PE Ratio
28.87
Volume
2,73,323.00
Day High - Low
681.55 - 646.00
52W High-Low
971.00 - 574.45
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
5,899.78 Cr
EPS
30.06
PE Ratio
28.87
PB Ratio
3.01
Book Value
225.71
EBITDA
474.50
Dividend Yield
0.73 %
Industry
Healthcare
Return on Equity
13.69
Debt to Equity
0.19
Analyst Rating and Forecast
- By Refinitiv from1 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
neutral
Aarti Pharmalabs Limited explains delay in regulatory disclosure due to official being on leave from February 3-5, 2026, causing inadvertent breach of 24-hour timeline.
neutral
Aarti Pharmalabs Limited issues corrigendum to fix typographical error in dividend record date intimation, correcting financial year reference from FY25 to FY26.
neutral
Aarti Pharmalabs reported Q3FY26 operational revenue of INR 4,253 Mn with EBITDA of INR 1,030 Mn. Company faces operational challenges at Atali facility while expanding Xanthine capacity to 9,000+ MTPA.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,801.60
#1 4,32,264.19
39.98
#1 54,729.00
9.71
#1 10,980
16.07
62.14
6,071.00
1,61,165.97
67.21
9,712.00
18.67
2,191
-1.02
38.37
4,390.00
1,48,577.55
66.21
11,539.40
6.99
1,911
26.24
61.73
1,292.30
1,07,859.28
19.93
33,741.20
16.73
5,725
-15.28
51.79
1,314.70
1,06,197.76
23.61
28,409.50
7.12
5,291
-57.18
40.42
2,314.90
1,05,744.36
23.07
22,909.50
13.74
3,306
#1 37.44
57.99
905.90
91,154.74
#1 18.35
23,511.00
18.55
4,615
-0.32
48.43
2,138.90
88,294.88
50.56
12,744.20
#1 20.90
2,007
7.65
47.71
1,296.50
75,300.93
21.89
32,345.60
9.43
3,484
7.59
66.14
5,355.50
64,033.04
26.89
13,458.30
3.70
2,216
1.90
40.57
Growth Rate
Revenue Growth
14.41 %
Net Income Growth
25.59 %
Cash Flow Change
53.25 %
ROE
10.94 %
ROCE
2.38 %
EBITDA Margin (Avg.)
6.08 %

Quarterly Financial Results

Quarterly Financials
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Revenue
463
457
532
472
486
459
441
450
508
558
463
543
562
388
418
437
Expenses
385
371
441
385
405
374
352
353
388
459
364
409
418
293
344
333
EBITDA
78
86
91
87
81
85
89
97
120
99
98
134
144
95
74
104
Operating Profit %
16 %
19 %
17 %
18 %
16 %
19 %
20 %
21 %
23 %
17 %
20 %
24 %
26 %
24 %
18 %
23 %
Depreciation
14
14
17
16
16
17
18
19
19
20
21
23
23
23
25
29
Interest
5
4
6
5
6
4
4
5
5
5
6
10
7
7
11
13
Profit Before Tax
60
68
69
65
59
64
67
74
96
74
72
101
115
65
39
63
Tax
11
16
18
17
16
17
15
21
31
18
17
27
26
16
11
15
Net Profit
49
52
51
48
43
47
52
53
65
56
55
74
88
50
28
48
EPS in ₹
5.39
5.72
5.64
5.26
4.73
5.20
5.72
5.82
7.20
6.12
6.03
8.16
9.75
5.46
3.08
5.29

Balance Sheet

Balance Sheet
2021
2022
2023
2024
2025
Total Assets
0
2,040
2,244
2,582
2,906
Fixed Assets
0
782
926
1,033
1,137
Current Assets
0
1,028
1,163
1,346
1,322
Capital Work in Progress
0
187
102
137
374
Investments
0
32
87
107
77
Other Assets
0
1,038
1,130
1,305
1,319
Total Equity & Liabilities
0
2,040
2,244
2,582
2,906
Current Liabilities
0
581
601
694
657
Non Current Liabilities
0
73
85
131
259
Total Equity
0
1,387
1,559
1,757
1,990
Reserve & Surplus
0
1,341
1,513
1,712
1,945
Share Capital
0
0
45
45
45

Cash Flow

Cash Flow
2021
2022
2023
2024
2025
Net Cash Flow
0
78
-71
12
-17
Investing Activities
0
-139
-158
-215
-414
Operating Activities
0
-44
250
216
332
Financing Activities
0
260
-164
10
65

Share Holding

% Holding
Jan 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Promoter
44.16 %
45.98 %
45.98 %
46.30 %
46.46 %
46.46 %
46.46 %
46.10 %
44.66 %
44.29 %
43.72 %
42.88 %
43.10 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
8.16 %
8.32 %
7.06 %
7.38 %
8.64 %
7.36 %
7.35 %
8.02 %
7.68 %
DIIs
14.73 %
13.70 %
10.66 %
10.51 %
9.91 %
9.97 %
11.47 %
11.35 %
10.36 %
7.53 %
7.80 %
6.96 %
7.66 %
Government
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
Public / Retail
24.66 %
28.35 %
30.23 %
29.13 %
29.74 %
29.71 %
29.57 %
29.45 %
30.39 %
34.10 %
34.43 %
35.39 %
34.85 %
Others
16.44 %
11.96 %
13.12 %
14.04 %
5.72 %
5.52 %
5.43 %
5.71 %
5.94 %
6.71 %
6.69 %
6.74 %
6.70 %
No of Share Holders
3,05,456
2,76,664
2,58,236
2,26,286
2,15,796
2,04,122
1,89,012
1,85,436
1,85,111
1,96,314
1,87,039
1,90,655
1,84,489

Dividend History

Annual Cash Flows 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.00 2 3 5 0.00
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.46 0.4 0.77 0.00

Announcements

Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 16, 2026
Clarification Regarding Delay In Disclosure Of Event To The ExchangeFeb 13, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 11, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 10, 2026
Corrigendum To Intimation Of Record Date For Dividend Dated February 09 2026.Feb 10, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 10, 2026
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSFeb 09, 2026
Fixation Of Record Date For Interim DividendFeb 09, 2026
Corporate Action-Board approves DividendFeb 09, 2026
Financial Results For The Quarter And Nine Months Ended December 31 2025Feb 09, 2026
Board Meeting Outcome for Outcome Of Board Meeting Held On February 9 2026Feb 09, 2026
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 06, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 02, 2026
Board Meeting Intimation for 1. Board Meeting Intimation For Unaudited Financial Results Of The Company For The Quarter And Nine-Months Ended December 31 2025 2. Declaration Of Interim Dividend If Any On The Equity Share Capital Of The Company For The FiJan 29, 2026
Clarification With Respect To Increase In VolumeJan 12, 2026
Clarification sought from Aarti Pharmalabs LtdJan 12, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 06, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementJan 01, 2026
Closure of Trading WindowDec 22, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 17, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 11, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 11, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationNov 11, 2025
Financial Results For Quarter And Half Year Ended September 30 2025Nov 09, 2025
Board Meeting Outcome for Board Meeting Outcome For Financial Results For The Quarter And Half Year Ended September 30 2025.Nov 09, 2025
Board Meeting Outcome for Board Meeting Outcome For Financial Results For The Quarter And Half Year Ended September 30 2025.Nov 09, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementNov 09, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 04, 2025
Board Meeting Intimation for Board Meeting Intimation For Approval Of Unaudited Standalone And Consolidated Financial Results For The Second Quarter And Half Year Ended September 30 2025Oct 27, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSOct 13, 2025
Ex-Parte Ad-Interim Injunction Order Regarding Pharmaceutical Drug Product Containing Ruxolitinib And/Or Ruxolitinib Phosphate APIOct 08, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 07, 2025
Closure of Trading WindowSep 25, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Sep 24, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationSep 23, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementSep 23, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 23, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 22, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 18, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 18, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 03, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 30, 2025
Reg. 34 (1) Annual Report.Aug 29, 2025
Business Responsibility and Sustainability Reporting (BRSR)Aug 29, 2025
Notice Of 6Th Annual General MeetingAug 29, 2025
Intimation Regarding 100 Days Campaign - Saksham NiveshakAug 21, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 20, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 20, 2025
Record Date For Final Dividend For FY 2024-25Aug 19, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 14, 2025

Technical Indicators

RSI(14)
Neutral
33.53
ATR(14)
Volatile
25.75
STOCH(9,6)
Neutral
22.86
STOCH RSI(14)
Neutral
22.75
MACD(12,26)
Bearish
-2.88
ADX(14)
Weak Trend
22.57
UO(9)
Bearish
45.00
ROC(12)
Downtrend And Accelerating
-5.80
WillR(14)
Oversold
-94.15